By Karen Roman
Biotech company Beacon Therapeutics Holdings Ltd announced the designation of Dr. Daniel Chung as its new Chief Medical Officer.
Dr. Chung has three decades of experience in clinical ophthalmology and academic research, and he formerly served as Chief Medical Officer at SparingVision, the company said in a statement.
Dr. Chung was also Ophthalmology Therapeutic Area Leader at Spark Therapeutics and participated in the development of Luxturna, the first gene therapy with FDA and EMA approval, it said.
“We are thrilled to welcome Dan to our leadership team,” said Lance Baldo, M.D., Beacon Therapeutics CEO. “He brings deep clinical and translational expertise in developing gene therapies for retinal diseases and has demonstrated an unwavering commitment to patients and the clinical community supporting blinding diseases.”
Contact:
